Navigation Links
CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
Date:5/11/2011

SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received.

CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been used as an antibacterial agent previously. CG400549 is being developed to target the notorious resistant bacterial strains such as MRSA (Methicillin Resistant Staphylococcus aureus) and VRSA (Vancomycin Resistant Staphylococcus aureus). CG400549 had successfully completed the Phase I Single Ascending Dose Study in Europe last year and has just received the draft CSR for the Phase I MAD study.

The objective of the MAD study was to evaluate safety, tolerability and pharmacokinetic characteristics of multiple ascending doses of CG400549 in healthy volunteers and a Phase IIa proof-of-concept study is anticipated to initiate as soon as the CSR is finalized.  

CG400549 has displayed remarkable in vitro and in vivo efficacy against some of the gold standard "superbug" therapeutics including Zyvox® and vancomycin as it demonstrated 4 to 8 fold better MICs, respectively. Prior to initiating clinical studies, several in vitro efficacy experiments were conducted at the laboratories of prominent infectious disease clinicians including Dr. Peter Applebaum's lab at the Hershey Medical Center.

Antibacterial resistance is a serious global health issue and one of the main culprits is the infections caused by Staphylococcus aureus such as MRSA. The number of MRSA infections in the United States has been increasing significantly as a 2007 report in Emerging Infectious Diseases, a publication of the
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and ... Stanley Global Healthcare Conference on Thursday, September 17, 2015. ... president of Lilly Oncology and Richard Gaynor , ... affairs for Lilly Oncology, will participate in a fireside ... A live audio webcast will be available on ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
(Date:8/28/2015)... ... ... An article published August 19th by the LA Times documented ... open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior pizza parlors ... current process, having already gone on for over a year, is taking much longer ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... ... , ... As reported by Medical Daily on August 22 , Cellfina, ... last for two years, the longest of any cellulite reduction system currently on the ... long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of the ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best ... sponsor of the “Music With A Mission” benefit concert in Mendon, IL. Held in ... to raise money to support music education programs in the underfunded local school districts ...
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... The Convenient Care Association,(CCA), a non-profit ... today announces it is in ongoing discussions,with ... Disease Control and,Prevention (CDC) to explore partnership ... services., During a recent meeting, the ...
... using fewer natural resources, CAMP HILL, Pa., April ... being green." But Highmark Blue Shield recognizes the impact ... and has,created and is in the process of implementing ... at Highmark include a variety of facility management,community and ...
... to rapidly measure minute amounts of insulin is a ... health of the bodys insulin-producing cells in real time. ... used to improve the efficacy of a new procedure ... the ability to free diabetics from insulin injections for ...
... Medicaid Funding Levels, 49th Nationally, Ill-Serves Ability,to Meet Growing ... Commenting on,yesterday,s release of the Institute of Medicine,s (IOM) ... Care Workforce," the,Texas Health Care Association (THCA) said the ... to meet the growing demand for care will,be severely ...
... YORK, April 15 An internationally-known brand name,New York ... Bruce,of Wellness" by Shape magazine, Susan Powter,s "Stop the ... personal story of losing over,l30 pounds as a single ... and fitness industry forever. Now, recently returned to public,life ...
... Experiences Year-over-Year Growth Since Founded, YARDLEY, Pa., ... of corporate performance management solutions, today,announced that 2008 ... services,revenue year- over-year for the past 10 years., ... the best solutions to,meet their business problems, whether ...
Cached Medicine News:Health News:CDC and Retail Health Clinic Leaders Explore Improving Prevention, Surveillance and Emergency Response 2Health News:Highmark Blue Shield Announces Sustainable, Eco-Friendly and Green Strategy 2Health News:Highmark Blue Shield Announces Sustainable, Eco-Friendly and Green Strategy 3Health News:Highmark Blue Shield Announces Sustainable, Eco-Friendly and Green Strategy 4Health News:New nanotube sensor can continuously monitor minute amounts of insulin 2Health News:New nanotube sensor can continuously monitor minute amounts of insulin 3Health News:Texas Health Care Association: New Report on Long Term Care Workforce Spotlights Need to Boost Texas Medicaid Rates 2Health News:Susan Powter The Politics of Stupid: The Cure for Obesity 2Health News:Breakaway Technologies Celebrates 10 Years in Business 2
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
... Utilizing the most complex grinding ... accurate trial lens, are specifically ... quality and precision as the ... marco RT-300 refractor. Marco custom ...
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Medicine Products: